Syros Pharmaceuticals (SYRS) Stock Statistics & Valuation Metrics

Syros Pharmaceuticals has a market cap or net worth of $2.68K. The enterprise value is -$77.45M.

Syros Pharmaceuticals has 26,832,457 shares outstanding. The number of shares has decreased by -2.65% in one year.

Syros Pharmaceuticals’s return on equity (ROE) is -9.88 and return on invested capital (ROIC) is -91.82%.

The current PE Ratio of Syros Pharmaceuticals is ―. Syros Pharmaceuticals’s PEG ratio is 0.06.

In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M and earned -164.57M in profits. Earnings per share was -5.81.

In the last 12 months, operating cash flow was -100.02M and capital expenditures -38.00K, giving a free cash flow of -100.06M billion.

Syros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Syros Pharmaceuticals upcoming earnings date is Nov 18, 2025, Before Open (Confirmed).

Syros Pharmaceuticals as a current ratio of 3.95, with Debt / Equity ratio of 372.55%

In the past 12 months, Syros Pharmaceuticals has paid 0.00 in taxes.

Syros Pharmaceuticals EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -1.30.

Syros Pharmaceuticals has $58.27M in cash and marketable securities with $60.23M in debt, giving a net cash position of -$1.95M billion.

Gross margin is 77.33%, with operating margin of -1298.19%, and net profit margin of -1656.34%.

The average price target for Syros Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold